2seventybio
Immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $286m Valuation: $286m | Acquisition | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (19 %) | 460 % | (78 %) | 68 % | 10 % | (62 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (313 %) | (728 %) | (46 %) | (574 %) | (274 %) | (185 %) | (347 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (366 %) | (724 %) | (48 %) | (536 %) | (278 %) | (217 %) | (151 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 367 % | 672 % | 119 % | 480 % | 272 % | 230 % | 203 % |
Source: Company filings or news article
Related Content
2seventy bio is a biotechnology startup dedicated to revolutionizing cancer treatment. The company's name, inspired by the speed of translating human thought into action (270 miles per hour), reflects its commitment to rapidly advancing cancer therapies. 2seventy bio aims to give people more time to enjoy life by developing innovative treatments that outmaneuver cancer.
The company operates in the biotechnology and healthcare market, focusing on discovering and developing new cancer therapies. It combines deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer. This approach allows 2seventy bio to create treatments that can significantly disrupt the current cancer treatment landscape.
2seventy bio serves patients diagnosed with cancer, healthcare providers, and the broader medical community. Its business model revolves around research and development (R&D) of novel cancer therapies, which are then brought to market through clinical trials and regulatory approval processes. The company generates revenue by commercializing these therapies, either by selling them directly or through partnerships and collaborations with other pharmaceutical companies.
In summary, 2seventy bio is a forward-thinking biotech company focused on developing groundbreaking cancer treatments. By leveraging advanced scientific knowledge and innovative approaches, it aims to provide patients with more time to live their lives fully.
Keywords: biotechnology, cancer treatment, innovative therapies, cell biology, genetics, immune response, healthcare, R&D, clinical trials, pharmaceutical partnerships.